Group Art Unit: 1621

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): A compound according to formula (I):

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\$$

wherein:

R is selected from the group consisting of:

 C_{2-6} alkyl (optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl); C_{2-6} alkenyl (optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl); C_{2-6} alkynyl (optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl); $(CH_2)_n$ — C_{3-6} carbocycle (optionally substituted by alkoxy, halogen, or C_{1-3} alkylsulfanyl); and $(CH_2)_n$ —R4, wherein R4 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane [[or]] and benzo[1,3]dioxole; R4 is optionally substituted by one or more substituents selected from Cl, Br, I, C_{1-3} alkyl (optionally substituted by one to three F) and C_{1-2} alkoxy (optionally substituted by one to three F);

R1 represents hydrogen or C₁₋₄ alkyl;

R2 represents C_{1-6} alkyl, ArC_{1-4} alkyl, wherein substitution is through the alkyl carbon, or Ar;

Ar is selected from the group consisting of phenyl, naphthyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolyl, imidazolyl, imidazolyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, and pyrimidyl; all of which may be unsubstituted or substituted by one or more Z₁ or Z₂ groups;

Group Art Unit: 1621

 Z_1 and Z_2 are, independently, selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, $(CH_2)_nCO_2R1$, C(O)NRR1, CN, $(CH_2)_nOH$, NO_2 , halogen, $N\underline{H}R_2$, and NHC(O)R2; and

n is an integer from 0 to 4; or a pharmaceutically acceptable salt thereof.

- 2. (Previously presented): A compound according to claim 1 selected from the group consisting of:
 - N-{2-[(Formylhydroxyamino)methyl]heptanoyl}benzenesulfonamide;
 - 4-Chloro-N-{2-[(formylhydroxyamino)methyl]heptanoyl} benzenesulfonamide;
 - 4-tert-Butyl-N-{2-[(formylhydroxyamino)methyl]heptanoyl} benzenesulfonamide;
 - N-{2-[(Formylhydroxyamino)methyl]heptanoyl}methanesulfonamide;
 - Butane-1-sulfonic acid

{2[(formylhydroxyamino)methyl]heptanoyl}amide;

- Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-heptanoyl} amide:
- 4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl}benzoic acid methyl ester;
- 4-Chloro-N-{2-[(formylhydroxyamino)methyl]-3-phenyl-propanoyl} benzenesulfonamide;
- N-{2-[(Formylhydroxyamino)methyl]-3-phenyl-propanoyl} benzenesulfonamide;
- 5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl] heptanoyl} amide;
- N-{2-[(Formylhydroxyamino)methyl]-4-phenyl-butanoyl} benzenesulfonamide;
- Butane-1-sulfonic acid {2-[(formylhydroxyamino)methyl]-4-phenyl-butanoyl}amide;
- Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-3-phenyl-propanoyl} amide;

Group Art Unit: 1621

- Biphenyl-4-sulfonic acid {2-[(formyl-hydroxy-amino)-methyl]-heptanoyl}-amide;
- 5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl] heptanoyl}amide;
- 4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl}benzoic acid propyl ester;
- Naphthalene-1-sulfonic acid {2-[(formylhydroxyamino)methyl] heptanoyl}amide;
- N-{2-[(Formylhydroxyamino)methyl]-5-methylhexanoyl} benzenesulfonamide;
- 5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-5-methyl-hexanoyl}amide;
- 4-Dimethylamino-N-{2-[(formylhydroxyamino)methyl]-5-methylhexanoyl} benzenesulfonamide;
- N-[2-(2,6-Dichloro-benzyl)-3-(formylhydroxyamino)propanoyl] benzenesulfonamide;
- Dimethylamino-N-{2-[(formylhydroxyamino)methyl]heptanoyl} benzenesulfonamide;
- 5-Methyl-pyridine-2-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino) propanoyl]amide;
- 5-Dimethylamino-naphthalene-1-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino)propanoyl]amide;
- N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methyl-benzenesulfonamide;
- N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-phenoxybenzenesulfonamide;
- N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methoxy-benzenesulfonamide;
- 5-Methyl-pyridine-2-sulfonic acid {3-(3,4-dichlorophenyl)-2-[(formylhydroxyamino) methyl]propanoyl}amide;
- N-{2-[(Formylhydroxyamino)methyl]hexanoyl}benzenesulfonamide;

Group Art Unit: 1621

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl] hexanoyl}amide;

- N-{2-[(Formylhydroxyamino)methyl]hexanoyl}-4-phenoxy-benzenesulfonamide;
- 5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-3-methyl-butanoyl}amide;
- 5-Dimethylamino-naphthalene-1-sulfonic acid {(R)-2-[(formylhydroxyamino)methyl] heptanoyl} amide;
- 5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]pentanoyl} amide;
- Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)methyl]pentanoyl} amide;
- Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)-methyl]-4-methyl-pentanoyl} amide; and
- 5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-4-methyl-pentanoyl}amide; or a pharmaceutically acceptable salt thereof.
- 3. (Currently amended): A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1[[;]] or a pharmaceutically acceptable salt thereof.
- 4. (Currently amended): A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.